Grace Therapeutics, Inc. Intangible Assets, Net (Excluding Goodwill)
Grace Therapeutics, Inc. (GRCE) had Intangible Assets, Net (Excluding Goodwill) of $27.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-13
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $27.59M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $41.13M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $41.13M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $41.13M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $27.59M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $41.13M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $41.13M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $41.13M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $41.13M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $41.13M 10-K · filed 2026-06-18 |
| 2024-12-31 | $41.13M 10-Q · filed 2025-02-13 |
| 2024-09-30 | $41.13M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $41.13M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $41.13M 10-K · filed 2025-06-23 |
| 2023-12-31 | $41.13M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $41.13M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $41.13M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $41.13M 10-K · filed 2024-06-21 |
| 2022-12-31 | $69.81M 10-Q · filed 2023-02-14 |
| 2022-09-30 | $69.81M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $69.81M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $69.81M 10-K · filed 2023-06-23 |
| 2021-12-31 | $65.21M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $65.21M 10-Q · filed 2021-11-10 |
| 2021-03-31 | $0.00 10-Q · filed 2022-02-14 |
| 2020-06-30 | $3.92M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $4.24M 10-K · filed 2021-06-22 |
| 2019-03-31 | $6.39M 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |